Seretide® substitute

Circassia’s particle-engineered formulation of the inhaled corticosteroid fluticasone propionate combined with the long-acting beta agonist salmeterol xinafoate is targeting direct substitution of GSK’s Seretide® delivered via pressurized metered dose inhaler (pMDI), which is used in the treatment of asthma.

Product progress

Circassia’s European product leverages the guidelines for orally inhaled products, which allow for approval without the need for large clinical trials. The product also has the potential to target other markets outside the USA.


Pipeline status: Seretide® substitute

Pre-clinicalPhase IPhase IIPhase III / PMA / SubstituteFiledApproved

View Circassia's full pipeline chart